Orano Med is a nuclear biotech company developing innovative therapies in oncology. Orano Med has developed new processes for producing lead-212 (²¹²Pb), a rare radioactive isotope used in Targeted Alpha Therapy (TAT), an innovative and promising approach of nuclear medicine allowing to recognize and destroy cancer cells while limiting the impact on nearby healthy cells.

With Macrocyclics and Pharma partners, Orano Med pursues the development of effective therapies to address patients’ needs. Orano Med is a subsidiary of the Orano group.